Antibody screening and binning has been blind - until now.
Get epitope bins AND locations in a single, high-throughput assay for comprehensive screening at the earliest stages of development.
Before you embark on lengthy and pricey engineering and maturation processes, identify your most promising candidates with unimpeachable evidence. We undertake a detailed structural characterization of your antigen, no matter how large or small, how complex, or how intractable to structural profiling it is (we’re looking at you, integral membrane proteins). Then, we evaluate binding of all of your antibody candidates, up to hundreds at a time, group them into bins, and map the rough location of each bin on the antigen.
Learn more about our approach and how it might benefit your antibody in our technical brief.
Our approach provides:
Antibody bins and locations on the antigen in one assay - learn why epitope binning via SPR/BLI isn’t enough
Detailed, higher-order structure of your target protein - no matter how big, how complex, or how challenging
Structure-informed binding sites at the earliest stages of antibody development - no more discovery in the dark!
Screening for biologics – get structural epitopes without compromising on the benefits of binning
Epitope binning, via techniques like SPR and BLI, is commonly used due to its speed, cost, and throughput - but binning gives no information about epitope location, residue involvement in binding, and target structure. But what if you could pursue a binning assay that gave you bins AND the location of those bins on the epitope - without compromising on the benefits binning provides? Read on to learn about how we enable just that - our high-resolution epitope profiling service provides structural bins so you can pursue structurally-informed antibody development at the earliest stages of discovery. That means no more surprises about epitope location, identity, or diversity (or lack thereof!).
Epitope binning is typically used in the early stages of drug development to categorize antibodies by their binding sites. Conventional approaches, like surface plasmon resonance or biolayer inferometry, have a major limitation: they give no information about the actual location or structure of the epitope on the antigen. Additionally, conventional epitope binning relies on a limited set of experimental conditions and may not capture the full range of antibody binding specificities. And without structural information, the interpretation of epitope binning results can be complex and subjective, resulting in inconclusive and failed experiments.
Our approach puts structure front-and-center - and we're the only technique on the market that provides structural bins for any antigen and antibody panel. We first characterize the higher-order structure of the antigen in detail using our patented, high-resolution protein footprinting platform. Then, we map the general binding site of each antibody, resulting in a map of epitope bins across a 3D structure of your antigen, even if your antigen doesn't have a known structure or can't be crystallized.
Submit the form below and we'll send the brief right to your inbox.
Our approach to high-resolution epitope profiling - antigen structure, epitope bins, and mapped bin locations
How we compare with and improve-upon conventional epitope binning via SPR or BLI
Ways to leverage the data for efficiency gains in antibody engineering, affinity maturation, and later development phases
An understanding of how structure can influence and enhance antibody development at the earliest stages
We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.
